Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia (AMICUS)
Schizophrenia is a mental health problem usually starting in the late teens/early twenties, and often lasting many years. The standard medication ('antipsychotics') for this problem is usually helpful, and if taken continually can keep people well, reducing the likelihood of further episodes. However, in up to one in three people with schizophrenia, the illness does not show much improvement with antipsychotic medication. For some of these 'resistant' illnesses, one particular antipsychotic, clozapine, can work well, but one disadvantage is the risk of a severe blood side effect which means that regular blood testing is necessary. If the response to clozapine treatment is disappointing, there is some evidence that adding another antipsychotic can sometimes produce more improvement. However, it seems that the added antipsychotic may need to be taken by the person for at least 10 weeks in order to work well. The investigators plan to test carefully the possible benefits and problems when the antipsychotic amisulpride or a dummy tablet ('placebo') is added to clozapine for 12 weeks in people whose schizophrenia illness has not been helped much by any antipsychotic medication on its own, and who are now taking clozapine, but again with not much improvement. The investigators have chosen amisulpride because its pharmacological action may be complementary to that of clozapine, and also it is less likely than some other antipsychotics to compound some of the characteristic side effects of clozapine, such as sedation, weight gain and other metabolic problems.
Adjunctive amisulpride or placebo will be randomly assigned. The investigators expect that adding amisulpride will be more likely to cause an improvement than adding placebo. But the investigators should learn more about the risks and side effects of combining these two medications. Also, the investigators should gain a greater understanding of the possible benefits of adding another antipsychotic to clozapine in relation to particular problem symptoms, and a person's ability to live and work in the community.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
|Official Title:||Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia|
- Total score on the Positive and Negative Syndrome Scale [ Time Frame: Baseline, and 6 and 12 weeks ] [ Designated as safety issue: No ]
- Social and Occupational Functioning Assessment Scale [ Time Frame: Baseline, and 6 and 12 weeks ] [ Designated as safety issue: No ]
- Calgary Depression Rating Scale for Schizophrenia [ Time Frame: Baseline, and 6 and 12 weeks ] [ Designated as safety issue: No ]
- Schedule for the Assessment of Insight [ Time Frame: Baseline, and 6 and 12 weeks ] [ Designated as safety issue: No ]
- Service Engagement Scale [ Time Frame: Baseline, and 6 and 12 weeks ] [ Designated as safety issue: No ]
- Antipsychotic Non-Neurological Side Effects Scale [ Time Frame: Baseline, and 6 and 12 weeks ] [ Designated as safety issue: Yes ]
|Study Start Date:||September 2011|
|Estimated Study Completion Date:||March 2014|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
Clozapine augmentation with another second-generation antipsychotic, amisulpride (400mg amisulpride for the first 4 weeks, then the option of titrating up to 800mg amisulpride for the remaining 8 weeks).
|Placebo Comparator: Placebo||
Clozapine augmentation with 1 capsule placebo for the first 4 weeks, then the option of titrating up to 2 capsules placebo for the remaining 8 weeks).
This 12-week, placebo-controlled RCT will be conducted in secondary care, specifically mental health services, at UK centres. The health technology to be assessed is the augmentation of clozapine treatment with another second-generation antipsychotic, amisulpride, which will be compared with placebo: 400mg amisulpride or 1 matching placebo capsule for the first 4 weeks, then the option of titrating up to 800mg amisulpride or 2 matching placebo capsules for the remaining 8 weeks. The study will be double-blind, with medication supplied as identical capsules containing either 400mg amisulpride or placebo. The optimum dose of clozapine at entry and subsequent augmentation will be achieved through a flexible dosing regimen whereby treating psychiatrists will be able to flexibly alter dose regimens to maximise clinical risk-benefit ratios; there will be opportunities for clinical titration of clozapine dose at two and six weeks. Any direct pharmacokinetic effect on clozapine levels will be assessed by pre- and post-augmentation plasma levels of clozapine, samples being taken at baseline and at the end of the 12 weeks. Recommended pharmacovigilance procedures will be followed. Clinicians will be asked not to prescribe any additional medication during the course of the study, and will be reminded of the drugs with potential adverse interactions, as mentioned in the SPCs for clozapine and amisulpride. Medication adherence will be assessed by 'pill count' and clozapine/norclozapine plasma level ratio.
Therapeutic improvement will be assessed in terms of overall symptom severity, but also using broader, clinically-relevant outcome measures of social and occupational function and target symptoms and/or behaviours as well as overall health status and utility. Side effects will be systematically assessed. The costs and outcomes for a cost effectiveness acceptability and net benefit analysis will also be measured. The primary economic measure will be the incremental cost effectiveness ratio of clozapine augmentation, estimated as the net cost of clozapine augmentation divided by net QALY of clozapine augmentation.
Twenty-four months will be allowed for recruitment of participants, plus 3 months for the final follow-up assessments.
|Contact: Thomas Barnes, MDemail@example.com|
|Imperial College London||Not yet recruiting|
|London, United Kingdom, W6 8LN|
|Contact: Thomas Barnes, MD 0207 386 1233 firstname.lastname@example.org|
|Principal Investigator: Thomas R Barnes, MD|
|University College London||Not yet recruiting|
|London, United Kingdom, NW3 2PF|
|Contact: David Osbourne, MD 0207 4726168 email@example.com|
|Principal Investigator: David Osborn, MD|
|Sub-Investigator: Louise Marston|
|Sub-Investigator: Michael King, MD|
|University of Manchester||Not yet recruiting|
|Manchester, United Kingdom, M13 9WL|
|Contact: Peter Haddad, MD 0161 7876007 firstname.lastname@example.org|
|Principal Investigator: Peter Haddad, MD|
|Principal Investigator: Andrew Proctor, MD|
|Sub-Investigator: Linda Davies|
|Principal Investigator:||Thomas R Barnes, MD||Imperial College London|